INT37556

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.14
First Reported 1987
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 12
Disease Relevance 7.77
Pain Relevance 1.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
arm 3
plasma 1
fat 1
brain 1
fat cells 1
Apo (Mus musculus)
Pain Link Frequency Relevance Heat
Dopamine 5 100.00 Very High Very High Very High
Catecholamine 60 99.96 Very High Very High Very High
antagonist 4 99.76 Very High Very High Very High
agonist 38 93.80 High High
Serotonin 1 84.80 Quite High
cocaine 1 76.64 Quite High
Morphine 1 75.68 Quite High
anesthesia 10 75.04 Quite High
noradrenaline 70 74.16 Quite High
Bile 8 71.20 Quite High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 730 100.00 Very High Very High Very High
Obesity 457 98.36 Very High Very High Very High
Nicotine Addiction 26 91.04 High High
Metabolic Syndrome 191 90.96 High High
Coronary Heart Disease 66 90.16 High High
Cardiovascular Disease 85 87.52 High High
Weight Loss 38 87.24 High High
Increased Venous Pressure Under Development 3 85.92 High High
Atherosclerosis 108 83.60 Quite High
Body Weight Changes 9 81.68 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The APO effect was neither mimicked by DA nor blocked by the D2DA antagonist domperidone, both of which fail to cross the blood-brain barrier to any significant extent.
Negative_regulation (blocked) of APO in brain associated with dopamine and antagonist
1) Confidence 0.14 Published 1987 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 3553538 Disease Relevance 0 Pain Relevance 0.74
At the highest dosing regimen, Apo AI and Apo E increased by 27% and 66% respectively, while Apo B decreased by 26% (Clark et al 2004).
Negative_regulation (decreased) of Apo B
2) Confidence 0.12 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2464766 Disease Relevance 0.64 Pain Relevance 0
Heterozygotes with a 40% decrease in CETP levels had a mean increase in HDL-C of 30% and no significant change in LDL-C levels, while homozygotes with complete loss of CETP levels had a greater than 100% increase in HDL-C and 40% decrease in LDL-C and Apo B levels (Inazu et al 1990; Koizumi et al 1991).
Negative_regulation (decrease) of Apo B associated with disorder of lipid metabolism
3) Confidence 0.12 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2464766 Disease Relevance 1.06 Pain Relevance 0.04
Thus, the effect of apo A-V on triglyceride level can be attributed to the intracellularly function of apo A-V to modulate hepatic VLDL synthesis and/or secretion.
Negative_regulation (effect) of apo
4) Confidence 0.10 Published 2005 Journal Lipids Health Dis Section Body Doc Link PMC545942 Disease Relevance 0.62 Pain Relevance 0
With respect to lipoprotein variables, both PED and MED arms showed reduction of apo B concentration and apo B/apo A-I at 8 weeks compared to baseline; however, only the PED arm exhibited continued reduction in both variables from 8 weeks to 12 weeks.
Negative_regulation (reduction) of apo B in arms
5) Confidence 0.05 Published 2008 Journal Nutr Metab (Lond) Section Body Doc Link PMC2588603 Disease Relevance 0.71 Pain Relevance 0
Subjects in both PED and MED arms showed significant reduction in non-HDL cholesterol and apo B/apo A-I at 8 weeks compared to baseline, but only the PED arm showed continued reduction in the ratio at 12 weeks.
Negative_regulation (reduction) of apo B in arm associated with disorder of lipid metabolism
6) Confidence 0.02 Published 2008 Journal Nutr Metab (Lond) Section Body Doc Link PMC2588603 Disease Relevance 0.90 Pain Relevance 0
Only the PED arm experienced increased HDL (P < 0.05) and decreased TG/HDL (P < 0.01), and continued reduction in apo B/apo A-I from 8 to 12 weeks.
Negative_regulation (reduction) of apo B in arm associated with disorder of lipid metabolism
7) Confidence 0.02 Published 2008 Journal Nutr Metab (Lond) Section Abstract Doc Link PMC2588603 Disease Relevance 1.16 Pain Relevance 0
Eight mice lacking apoB100 (Mttp?
Negative_regulation (lacking) of apoB100
8) Confidence 0.02 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2582480 Disease Relevance 0.06 Pain Relevance 0
Patients with FCHL have increased apoB100 levels and decreasing catecholamine-induced lipolysis but the fat cell size remains normal, suggesting a link between low lipolysis and low lipid synthesis in fat cells.
Negative_regulation (decreasing) of apoB100 in fat cells associated with catecholamine and obesity
9) Confidence 0.02 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2582480 Disease Relevance 0.80 Pain Relevance 0.13
This recombination results in the termination of hepatic VLDL synthesis and depletion of plasma apoB100, as described [6].
Negative_regulation (depletion) of apoB100 in plasma
10) Confidence 0.02 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2582480 Disease Relevance 0.38 Pain Relevance 0.14
Mice lacking apoB100 also had higher oxygen consumption and lipid oxidation.
Negative_regulation (lacking) of apoB100
11) Confidence 0.02 Published 2008 Journal PLoS ONE Section Abstract Doc Link PMC2582480 Disease Relevance 0.88 Pain Relevance 0.07
These results suggest that mice lacking apoB100 decrease their circulating lipids rather than body fat as a result of the increase in catecholamine-induced lipolysis by enhancing energy expenditure and fat oxidation.


Negative_regulation (lacking) of apoB100 in fat associated with catecholamine
12) Confidence 0.01 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2582480 Disease Relevance 0.49 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox